Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making (2012)

In its second annual survey of key health care stakeholders, NPC, working with the public health research firm Social & Scientific Systems (SSS), examined the environment for health care decisions, especially the current state of CER and its impact on medical decision making.

The purpose was to set a baseline for where key stakeholders believe we are today on CER and for tracking progress and judging future effects. According to the findings, there is clear recognition among key health care influentials about the importance of CER and its promise for the future. These stakeholders also expressed tempered optimism about progress in efforts to provide or improve the tools necessary for this research, and that any significant effects of CER are yet to be realized, and much work remains to be done.

CER Survey Highlights:

In its second survey to gauge attitudes around comparative effectiveness research (CER), the National Pharmaceutical Council was able to capture shifts in the conversation. 

CER continues to be a key issue of importance to stakeholders, but perceived importance has leveled off between 2011 and 2012.

  • More than half (53 percent) of survey respondents were “very familiar” with comparative effectiveness research and one-third of respondents were “somewhat familiar” with CER.
  • Of survey respondents, 95 percent said that CER was “somewhat” or “very important” to them or their organizations, a small increase from the 91 percent cited a year earlier.
  • However, the percentage that said CER was very important was lower than in the previous survey, declining from 71 percent to 64 percent. 

The Patient Centered Outcomes Research Institute (PCORI) continues to be recognized as an important player in CER.

  • Audiences who were “somewhat” to “very” familiar with PCORI rose by 8 percent over last year, increasing from 70 percent to 78 percent.
  • Between the 2011 survey and the 2012, PCORI showed the biggest jumps in recognition in key areas, compared to other organizations including the Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), Food and Drug Administration (FDA), private payers, academia and pharmaceutical industry. 
  • Stakeholders’ expectations of PCORI’s influence jumped most dramatically in two areas:
    • Establishing research standards – from 50 percent to 72 percent
    • Funding and monitoring research – from 44 percent to 60 percent

However, in key areas of importance, PCORI has yet to assume a leadership position among stakeholders. Survey respondents ranked who they thought would be the most important influencers in the next five years within these areas:

Who will help establish research standards around CER?

  1. AHRQ (83 percent)
  2. PCORI (72 percent)
  3. NIH (60 percent)

Who will establish research priorities?

  1. AHRQ (77 percent)
  2. NIH (71 percent)
  3. PCORI (67 percent)

Who will fund and monitor research?

  1. NIH (85 percent)
  2. AHRQ (74 percent)
  3. Pharmaceutical Medical Products Industry (66 percent)

(PCORI was rated 60 percent)

Who will conduct comparative effectiveness research?

  1. Academia (88 percent)
  2. Pharmaceutical Medical Products Industry (70 percent)
  3. NIH (50 percent)

Expectations are still strong that CER will improve health care decision-making, but few expect that impact to be felt soon.

  • In the next year, only 30 percent of respondents felt CER would moderately or substantially improve health care decision-making
  • In the next three years, 77 percent expected improvement
  • In the next five years, 91 percent expected improvement

CER Survey Parameters:

The survey, conducted from October 2011-February 2012, targeted key stakeholders who have an impact on, or are affected by, research involving medical effectiveness, including researchers/thought leaders; government; insurers and health plans; employers; business coalitions/HR specialists; and associations/trade groups. A total of 117 stakeholders participated.

Survey materials:

Newsletter Volume

E.V.I.dently August 2014

NPC MessageHealth and Productivity Go Hand in HandClosely tied to the productivity and prosperity of our nation is the health and safety of its...
Blog Post

CER Tweets of the Week: How Effective is CER?; PCORI Funding Opportunities; Big Data in Health Care (August 18-22)

How effective is comparative effectiveness research (CER)? This week on Twitter, health care stakeholders shared NPC Chief Science Officer Dr. Robert...
Blog Post

CER Tweets of the Week: All Things Patient (August 11-15)

This week’s comparative effectiveness research (CER) tweets revolve around patient-centric news. The Patient-Centered Outcomes Research Institute’s (...
Blog Post

CER Tweets of the Week: Will CER Really Deliver Better Patient Outcomes? (August 4-8)

Comparative effectiveness research (CER) stakeholders shared news about the Patient-Centered Outcomes Research Institute’s next funding round with...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Developing Usability Criteria for Comparative Effectiveness Research

Avalere Health Senior Manager Sung Hee Choe outlines her work with the National Health Council to bring stakeholders together to develop the criteria...
Blog Post

CER Tweets of the Week: How Effective is CER?; PCORI Funding Opportunities; Big Data in Health Care (August 18-22)

How effective is comparative effectiveness research (CER)? This week on Twitter, health care stakeholders shared NPC Chief Science Officer Dr. Robert...
Blog Post

CER Tweets of the Week: All Things Patient (August 11-15)

This week’s comparative effectiveness research (CER) tweets revolve around patient-centric news. The Patient-Centered Outcomes Research Institute’s (...
Blog Post

CER Tweets of the Week: Will CER Really Deliver Better Patient Outcomes? (August 4-8)

Comparative effectiveness research (CER) stakeholders shared news about the Patient-Centered Outcomes Research Institute’s next funding round with...
Blog Post

PCORI Grants, HEOR & FDA Guidance Top CER Tweets of the Week (July 21-25)

What were some of the popular comparative effectiveness research (CER)-related topics on Twitter this week? We saw keen interest in the Patient-...

Research

  •  
  • 1 of 11
  • >

Commentary & Testimony